Isomorphic Labs is Alphabet's play in AI drug discovery – TechCrunch

The field of drug discovery has been supercharged by the capabilities of AI, which several companies have applied in various ways to turn an enormous practical problem into a tractable information problem. The latest to do so is Google parent company Alphabet, which has established Isomorphic Labs, under DeepMind head Demis Hassabis, to take its shot at the promising new field. Very little was revealed about the company in its debut blog post and a very general accompanying FAQ. The aim of the company is to "build a computational platform to understand biological systems from first principles to discover new ways to treat disease." There are, of course, a few assumptions baked into that founding statement, most prominently that it's possible to computationally simulate biological systems in a matter conducive to drug discovery.